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ABSTRACT: Undesirable side eﬀects associated with orthos-
teric agonists/antagonists of cannabinoid 1 receptor (CB1R), a
tractable target for treating several pathologies aﬀecting
humans, have greatly limited their translational potential.
Recent discovery of CB1R negative allosteric modulators
(NAMs) has renewed interest in CB1R by oﬀering a
potentially safer therapeutic avenue. To elucidate the CB1R
allosteric binding motif and thereby facilitate rational drug
discovery, we report the synthesis and biochemical character-
ization of ﬁrst covalent ligands designed to bind irreversibly to
the CB1R allosteric site. Either an electrophilic or a
photoactivatable group was introduced at key positions of two classical CB1R NAMs: Org27569 (1) and PSNCBAM-1 (2).
Among these, 20 (GAT100) emerged as the most potent NAM in functional assays, did not exhibit inverse agonism, and
behaved as a robust positive allosteric modulator of binding of orthosteric agonist CP55,940. This novel covalent probe can serve
as a useful tool for characterizing CB1R allosteric ligand-binding motifs.
■ INTRODUCTION
Constituents of the endocannabinoid biosignaling system
include two principal cannabinoid G-protein-coupled receptors
(GPCRs) 1 and 2 (CB1R and CB2R, respectively), their main
endogenous cannabinergic ligands (anandamide, AEA; 2-
arachidonoylglycerol, 2-AG), and enzymes responsible for
endocannabinoid biosynthesis and inactivation.1−4 Expressed
in various peripheral tissues, CB1R is the most abundant class-
A GPCR in brain.5,6 CB1R-mediated signaling helps regulate
many important physiological functions including learning,
memory, and cognition, nociception, cardiovascular function,
reproduction, and neuronal development. Dysregulated CB1R
activity has been implicated in the pathogenesis of disease states
related to these and other physiological processes such that
small-molecule modulators of CB1R-mediated signaling are
considered to have therapeutic potential.1,3 On the other hand,
CB2R is mainly expressed in peripheral tissues, particularly
immune cells7,8 as well as CNS microglia9 and has been
pursued for treating pain and inﬂammation.10−17 In the past
two decades, structurally diverse, potent, and selective CB1R
orthosteric agonists have been identiﬁed with (pre)clinical
eﬃcacy in treating nausea, emesis, and multiple sclerosis and
managing glaucoma, pain, and inﬂammatory disorders.18−20
Their salutary eﬀects notwithstanding, CB1R orthosteric
agonists have been associated with adverse events including
mood alteration (euphoria, anxiety, panic), acute psychoses,
and impaired cognition and motor performance, which limit
their clinical utility.21 Several CB1R-selective antagonists/
inverse agonists have also emerged as potential drugs for
cardiometabolic diseases and nicotine- and alcohol-use
disorders. Reminiscent of CB1R orthosteric agonists, however,
therapeutic application of CB1R orthosteric antagonists/inverse
agonists is severely restricted by the potential for unacceptable
psychotropic side eﬀects including depression, social aversion,
and suicidal ideation.3,21−25
As has been demonstrated for several other class-A GPCRs,
CB1R has allosteric sites spatially distinct from the orthosteric
ligand-binding pocket, and allosteric modulators with CB1R
selectivity vs CB2R have been identiﬁed.26−29 Engagement of
CB1R by allosteric modulators is believed to induce a
conformational change in the receptor that may be diﬃcult
to achieve with orthosteric ligands alone and “ﬁne-tune” the
pharmacological activity of the orthosteric ligand.30−32 Due to
their generally enhanced CB1R selectivity, reduced inter-
receptor promiscuity, and higher-resolution functional control
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of receptor information transmission, CB1R allosteric modu-
lators are anticipated to oﬀer several therapeutic advantages
over orthosteric ligands.
Exemplars of well-studied, structurally distinct CB1R-
selective allosteric ligands are shown in Figure 1. These include
5-chloro-3-ethyl-N-(4-(piperidin-1-yl)phenethyl)-1H-indole-2-
carboxamide (1, Org27569)26 and 1-(4-chlorophenyl)-3-(3-(6-
(pyrrolidin-1-yl)pyridine-2-yl)phenyl)urea (2, PSNCBAM-1),27
two CB1R allosteric modulators that emerged from initial
structure−activity relationship (SAR) studies on high-through-
put screening (HTS) leads. Although 1 and 2 exhibit several
characteristic properties of allosteric modulators, they elicit
markedly divergent eﬀects on the aﬃnity and eﬃcacy of the
standard cannabinoid-receptor orthosteric ligand 2-
[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-
methyloctan-2-yl)phenol (CP55,940). Compounds 1 and 2
behave as both a positive allosteric modulator (PAM) of
CP55,940 binding aﬃnity and a negative allosteric modulator
(NAM) of CP55,940 signaling eﬃcacy and potency. Addition-
ally, endogenous CB1R allosteric modulators have been
identiﬁed and characterized. The nonclassical eicosanoid
(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-
tetraenoic acid (3, lipoxin A4), whose traditional biological
target is the formyl peptide receptor FPR1, was also shown to
function as CB1R PAM of orthosteric ligand binding and
adenylyl cyclase activity.28 The endogenous steroid 1-
((3S,8S,9S,10R,13S,14S,17R)-3-hydroxy-10,12,13-trimethyl-
2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-
cyclopenta[a]phenanthren-17-yl)ethan-1-one (4, pregneno-
lone) acts as a CB1R NAM functionally (CB1R-mediated
ERK1/2 phosphorylation) without any eﬀect on orthosteric
agonist binding aﬃnity.29 The dopamine transport inhibitor
RTI-37133 and the PPAR-α agonist fenoﬁbrate have also been
suggested to act at a CB1R allosteric site.34 Very recently, we
have shown that cannabidiol, the nonpsychoactive constituent
of Cannabis sativa, exhibits negative allosteric modulation at
CB1R.35 Additionally, ligands displaying positive allosteric
modulation of orthosteric ligand’s binding and function have
been reported recently.36,37 These collective ﬁndings substan-
tiate the existence and functional signiﬁcance of allosteric sites
on CB1R whose pharmacological modulation of endogenous/
orthosteric ligand activity could be exploited for therapeutic
ends.
Although it has been a decade since the ﬁrst CB1 NAM (1)
was reported, no new CB1 NAM with improved potency/
eﬃcacy has been identiﬁed that has been studied in vivo. To
date, very limited in vivo studies with 1 and 2 have been
reported where these NAMs have shown moderate eﬃ-
cacy.27,38−40 Another major limitation associated with these
two compounds is that they exhibit CB1R inverse agonism in
addition to having NAM activity.26,41,42 For establishing
therapeutic utility of CB1 NAMs, there is a need for developing
potent and eﬃcacious CB1R NAMs that lack inverse agonism
so as to avoid related side eﬀects.
To inform rational drug design aimed at therapeutic CB1R
allosteric modulation, it is critical to expand our currently
limited knowledge of the structural properties and functional
inﬂuence of the receptor’s allosteric ligand-binding site(s).
Although candidate atomic-level interactions involved in GPCR
ligand recognition and functionally productive engagement can
be extrapolated from ligand−receptor cocrystals, a CB1R
crystal structure has remained elusive, and its inherently static
nature precludes direct observation of structure−function
correlates of CB1R (allosteric) ligands. Although homology
modeling and mutation studies have allowed some character-
ization of the properties of CB1R’s allosteric ligand-binding
domain, these approaches per se cannot aﬀord direct
experimental observation of the molecular nature of ligand−
CB1R interaction and its consequences for cell signaling, since
even conservative, single amino-acid mutations may alter
inadvertently receptor conformation and function.41−44 We
have incorporated an alternative approach for interrogating
directly the structure−function correlates of ligand binding to
druggable protein targets (enzymes, GPCRs) in their functional
state and under physiological conditions.45−49 Globally, this
experimental paradigm, termed ligand-assisted protein structure
(LAPS), integrates information from point mutations, molec-
ular modeling, and peptide-level tandem mass spectrometry
studies on ligand−receptor complexes to identify amino acid
residues within (or in the immediate vicinity of) the ligand-
binding domain critical to ligand engagement and activity.49
Pharmacologically active ligands of diverse chemical classes
purpose-designed to carry reactive groups as high-aﬃnity, site-
directed covalent probes are key elements foundational to the
LAPS experimental paradigm. Various reactive groups, both
electrophilic (e.g., isothiocyanate, benzophenone, etc.) and
photoactivatable (triﬂuoromethyl diazirine, aliphatic/aromatic
azides, etc.) type, can be incorporated at key positions into a
noncovalent parent ligand to render the parent ligand capable
of reacting in a chemically deﬁned manner with a distinct
amino acid specie.50−52 For this purpose, and in recognition of
the importance of cysteine residues to protein structure and
Figure 1. Representative CB1R allosteric modulators reported in the literature.
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function, we have successfully exploited the spontaneous,
preferential reactivity at physiological pH between isothiocya-
nate (NCS)-functionalized electrophilic ligands and target-
protein cysteine nucleophiles.46,53−56 The isothiocyanate
functionality exhibits pronounced reactivity toward amine
nucleophiles and sulfhydryl groups of cysteine with poor ability
to react with other nucleophiles such as alcohol or water.
The successful design and utilization of covalent aﬃnity
probes in LAPS and other experimental applications to help
characterize experimentally the orthosteric ligand-binding
domains of CB1R and other cannabinoid-system protein
therapeutic targets60−62,47,57,58 prompted the current work
aimed at generating a focused library of electrophilic and
photoaﬃnity probes carrying covalently reacting groups and
targeted to the CB1R allosteric site(s). The design approach
was based on the rational derivatization of two well-studied
CB1R allosteric ligands, 1 and 2 (Figure 1), guided by the
existing SAR data. Our results document the successful
extension of the application of orthosteric CB1R covalently
reactive probes to the receptor’s allosteric site(s) and constitute
the ﬁrst identiﬁcation and functional proﬁling of a novel,
covalent, allosteric CB1R aﬃnity probe.
■ CHEMISTRY
From precedent structure−activity relationship studies con-
ducted by us40 and others59−64 on the two CB1R allosteric
modulators 1 and 2, we identiﬁed two sites on the molecule,
the C3 and C5 positions of 1, and the C-4 position of 2,
important to the overall allosteric activity of these compounds.
A focused library of seven analogues with electrophilic
(isothiocyanate) or photoaﬃnity (azide or benzophenone)
warheads placed at the terminal carbon of the C3 side chain
and at the C5 position on parent molecule 1, and at the C-4
positon of 2 were synthesized, generating the novel analogues
19, 20, 25, 26, 33, 34, and 36 containing covalently reacting
groups (Schemes 1−5).
The novel indole-2-carboxamide analogues (19, 20, 25, and
26) of 1 were constructed as shown in Schemes 3 and 4. The
C5-substituted indole rings were synthesized with an eﬃcient
method that utilizes Fisher cyclization on a mixture of azo and
hydrazone of the corresponding diazonium salts (Scheme 2).
The ﬁnal carboxamide derivatives were synthesized using
carbodiimide based amidation of the substituted indole-2-
carboxylic acids with piperidinyl phenethylamine synthesized as
per Scheme 1.
N-Arylation of commercially available 4-ﬂuorobenzaldehyde
(5) with piperidine gave 4-piperidinylbenzaldehyde (6).65 To
access the substituted nitrostyrene 7, we employed the Henry
reaction on 6 in the presence of ammonium acetate in
nitromethane as a solvent. Direct conversion of 7 to the desired
amine 8 using LiAlH4, according to a previously published
protocol, required 48 h, and the product was isolated in low
yield.66 Alternatively, a route involving ﬁrst the reduction of the
double bond on 7 with NaBH4 followed by reduction of nitro
group with in situ-generated nickel borohydride gave 8 in high
yield (Scheme 1).
Scheme 2 describes the synthesis of the key substituted-
indole esters. The alkylation of ethyl acetoacetate using
(substituted) alkyl halides (11) in the presence of sodium
ethoxide gave β-ketoesters (12) as the ﬁrst step. Condensation
Scheme 1. Synthesis of Piperidinyl Phenethylamine 8a
aReagents and conditions: (a) piperidine, K2CO3, anhyd NMP, 135 °C, 12 h; (b) CH3NO2, NH4OAc, reﬂux, 2 h; (c) (i) NaBH4, MeOH, 5 °C to rt,
2 h; (ii) NiCl2·6H2O, NaBH4, THF:MeOH (95:5), 0 °C, 3 h.
Scheme 2. Synthesis of Substituted Indole-2-carboxylates 15a, 15b, and 15ca
aReagent and conditions: (a) NaNO2, HCl, 0 °C, 1 h; (b) NaOEt, EtOH, 12 h, reﬂux; (c) CH3COONa, EtOH, 0 °C, 3 h; (d) 20% H2SO4, EtOH,
reﬂux, 24 h.
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of 12 with freshly prepared diazonium salts 10 (obtained from
substituted anilines 9) in the presence of sodium acetate gave a
mixture of azos (13) and hydrazones (14) as per the Japp−
Klingeman reaction. These intermediates (13, 14) were isolated
as a mixture by passing the reaction crude product over a small
silica gel column, and in the case of 12c the reaction yielded
only the azo compound 13c.67 This was followed by Fisher
cyclization in 20% ethanolic sulfuric acid to give the chloro
indole ester (15a), the nitro indole ester (15b), and the
phthalimido indole ester (15c) in 57−71% yields.
The azido (19) and isothiocyanate (20) analogues of 1 were
constructed as depicted in Scheme 3. Base-catalyzed hydrolysis
of the nitro indole ester (15b) gave acid (16b) in high yield.
Coupling of 16b with 8 yielded the nitro indole-2-carboxamide
(17). Similarly, 15a was used to synthesize 1. The nitro
functionality of 17 was eﬃciently reduced to the amino indole-
2-carboxamide (18) using in situ-generated nickel borohydride.
Treatment of 18 with a mixture of tert-butyl nitrite and azido
trimethylsilane yielded 5-azido-3-ethyl-N-(4-(piperidin-1-yl)-
phenethyl)-1H-indole-2-carboxamide (19). Compound 18
was also served as a precursor to synthesize the corresponding
Scheme 3. Synthesis of 3-Ethylindole-2-carboxamides 19 and 20a
aReagents and conditions: (a) dioxane:H2O (10:1), KOH, reﬂux, 2 h, acidic workup; (b) EDCI, HOBt, DIPEA, NMP, rt, overnight; (c) NiCl2·
6H2O, NaBH4, THF:CH3OH (13:1), −5 °C, 1 h; (d) t-BuONO, TMSN3, THF, rt, 3 h, (e) di(2-pyridyl)thionocarbonate, CH2Cl2, rt, 15 min.
Scheme 4. Synthesis of 5-Chloroindole-2-carboxamides 25 and 26a
aReagents and conditions: (a) (i) ethanolamine, EtOH, reﬂux, 14 h; (ii) KOH, dioxane:H2O (4:1), reﬂux, overnight; (b) Boc-anhydride, THF, aq
NaHCO3 soln, 0 °C (3 h) to rt (24 h); (c) EDCI, HOBT, DIPEA, NMP, rt, overnight; (d) TFA:CH2Cl2 (1:10), rt, 3 h; (e) K2CO3, CuSO4,
CH3OH:H2O (20:1), TfN3 in CH2Cl2, rt, 18 h; (f) di(2-pyridyl)thionocarbonate, CH2Cl2, rt, 15 min.
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isothiocyanate analogue (20) in the presence of di-2-pyridyl
thionocarbonate (DPT) at room temperature.
Phthalimido indole ester (15c) was treated with ethanol-
amine to give a lactam intermediate which was hydrolyzed
using KOH to give the acid (21) (Scheme 4). The amino group
in 21 was protected using Boc-anhydride to provide 22 which
upon coupling with 8 in the presence of EDCI aﬀorded 23.
TFA-mediated deprotection of the NH-Boc group on 23 led to
the amino analogue (24). The azido analogue (25) was then
obtained by treating 24 with in situ-generated triﬂuorometha-
nesulfonyl azide. Direct conversion of 24 into the correspond-
ing isothiocyanate analogue (26) was carried out at room
temperature using DPT.
Analogues of 2 (33, 34, and 36) were synthesized as shown
in Scheme 5. Treatment of 2,6-dibromopyridine (27) with neat
pyrrolidine (28; excess) gave pyrrolidinyl bromopyridine (30)
in quantitative yield. Microwave-accelerated Suzuki coupling of
29 with m-nitrophenylboronic acid in the presence of catalytic
Pd(PPh3)4 aﬀorded intermediate 30 which was further reduced
to amine (31) in the presence of Raney-nickel under a
hydrogen atmosphere. The isocyanate intermediate was
synthesized in situ by treating 31 with triphosgene in the
presence of triethylamine and was then reacted with 4-
azidoaniline (32) in the presence of triethylamine to aﬀord
the desired product 33. It was then converted to the
isothiocyanate analogue (34) by treating 33 with triphenyl-
phosphine followed by exposure to CS2 (Staudinger/Aza-Wittig
reaction).68 Commercially available benzophenone aniline (35)
upon treatment with triphosgene in the presence of triethyl-
amine gave corresponding isocyanate which was further reacted
with 31 to yield the desired benzophenone-containing probe
(36).
■ RESULTS AND DISCUSSION
Following the discovery of 1, substantial SAR studies around it
revealed that the indole-2-carboxamide scaﬀold is a promising
template through which CB1R allosteric modulators with
improved aﬃnity, eﬃcacy, potency, and pharmacokinetics
could be generated. These studies identiﬁed several key
pharmacophoric features within this structural class that
inﬂuence their binding and functional properties.59,61−63 For
example, the indole ring is more important for ligand aﬃnity
with the allosteric site than for its ability to modulate ligand
binding at the orthosteric site (allosteric cooperativity). Alkyl
chain length at the C3 position and the substitutions on the C5
position of the indole ring signiﬁcantly impact allosteric aﬃnity
as well as cooperativity at CB1R.62,63 Replacing the amide
linkage with ester functionality or modulating ethylene linker
length between the amide bond and the phenyl ring drastically
reduces the allosteric cooperativity toward binding.60,62,64
Replacing the piperidinyl group with a dimethylamino group
signiﬁcantly increases the allosteric cooperativity, and groups
such as methyl, methylamino, nitro, and chloro but not ﬂuoro,
pyrrolidinyl, or 4-methylpiperazinyl were somewhat toler-
ated.62,64 Along similar lines, SAR reported around 2 from
us40 and others61 has enabled identiﬁcation of critical positions
(especially the C-4 position) on this molecule that aﬀects
CB1R orthosteric ligand binding and downstream signaling.
The commonality of the key phamacophoric features of 1 and
2, their SAR trends, and their unique and paradoxical
pharmacological proﬁle at CB1R strongly suggest that both
may be acting through the same allosteric site on CB1R.
Scheme 5. Synthesis of Diarylureas 33, 34, and 36a
aReagent and conditions: (a) neat, rt, 1 h; (b) Ba(OH)2, Pd[P(Ph)3]4, DME:H2O (5:2), 150 °C, M.W., 15 min; (c) Raney-nickel, H2, MeOH, rt, 3
h; (d) triphosgene, Et3N, toluene, 70 °C, 3 h; (e) Et3N, DCM, 0 °C, 6 h; (f) (i) TPP, reﬂux, 4 h, benzene; (ii) CS2, 40 °C, 12 h; (g) triphosgene,
Et3N, toluene, 70 °C, 3 h; (h) THF, 0 °C to rt, 6 h.
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■ FUNCTIONAL CHARACTERIZATION
A focused library of analogues bearing reactive warheads placed
at the terminal carbon of the C3 side chain and at C5 positions
on parent molecule 1 (analogues 19, 20, 25, and 26) and at the
C4 positon of 2 (analogues 33, 34, and 36) were biochemically
evaluated in a series of assays. As these analogues were expected
to potentially exhibit the “aﬃnity vs eﬃcacy paradox” similar to
the parent compounds,26,41 and as a CB1 NAM having
functional potency but no eﬀect on orthosteric ligand binding
has been identiﬁed,29 we chose to ﬁrst characterize these newly
synthesized analogues in two key functional assays. We
characterized both the parent compounds and their analogues
in CHO-K1 cells stably expressing human CB1R (hCB1R) by
using the PathHunter β-arrestin and HitHunter cAMP cell-
based functional assays. The PathHunter technology indexes
the ability of a test agent to aﬀect the recruitment and binding
of the pleiotropic scaﬀold protein β-arrestin following kinase
phosphorylation of agonist-bound CB1R, a process that
uncouples the phosphorylated CB1R from its cognate G
protein (routinely, Gi), subsequently targeting the receptor for
internalization and enabling the recruitment of signal trans-
ducers by the internalizing CB1R−β-arrestin complex. The
HitHunter assay indexes the ability of a test agent to modulate
forskolin-stimulated cellular adenylyl cyclase activity (i.e.,
cellular cAMP formation). Notably, β-arrestin-mediated signal-
ing is independent of both G proteins and classical second
messengers, whereas the HitHunter cAMP assay reﬂects signal
transduction dependent upon G-proteins and cAMP as second
messenger.41,69,70
The parent compounds as well as their covalent analogues
inhibited cellular CB1R-dependent β-arrestin recruitment and
cAMP accumulation with nanomolar potencies (Figures 2 and
3 and Tables 1 and 2). The negative allosteric modulatory
activity of both 1 and 2 in the β-arrestin and cAMP assays is
congruent with previous observations (Table 1 and 2).41
Covalent analogues of 1 exhibited a 14- to 83-fold greater
potency, and slightly greater eﬃcacy, in inhibiting β-arrestin
recruitment as compared to their eﬀect on cellular cAMP
accumulation (Figure 2, Table 1). Similarly, covalent analogues
of 2 also exhibited greater potency in the β-arrestin vs cAMP
assay, but the magnitude of the diﬀerence (3- to 19-fold) was
not as great as that displayed by the covalent analogues of 1
(Figure 3, Table 2). Among these probes, 20 was the most
potent inhibitor of β-arrestin recruitment (EC50 = 2 nM) and
exhibited appreciable activity in the cAMP assay (EC50 = 174
nM) (Table 1). Compound 20 was more potent and eﬃcacious
than the parent compound, 1, in both β-arrestin and cAMP
assays (Figure 2, Table 1) and exhibited the highest functional
selectivity (83-fold) for β-arrestin vs cAMP. When the azide
group was attached to the terminal carbon of the ethyl chain at
the C3 position (25), the ability of the analogue to inhibit
forskolin-stimulated cAMP accumulation (EC50 = 1120 nM), as
well as its ability to inhibit β-arrestin recruitment (EC50 = 64
nM), was signiﬁcantly compromised. Interestingly, placing the
isothiocyanate group at the terminal carbon of the alkyl chain at
the C3 position (26) abrogated activity in the cAMP assay
(EC50 > 10 000 nM) and reduced activity in the β-arrestin assay
by 2 orders of magnitude (EC50 = 209 nM). Compound 19
displayed activity similar to that of 1 in the cAMP assay but had
modest activity in the β-arrestin assay (Table 1). None of the
covalent analogues of 2 displayed a better activity proﬁle than
the parent in either the β-arrestin or the cAMP assay (Table 2).
Although the azide (33) and the isothiocyanate (34) analogues
showed reduced potencies in the cAMP assay (EC50 = 166 nM
and 118 nM, respectively) compared to parent compound 2
(EC50 = 71 nM), they were some 2- to 3-fold more potent than
1 (EC50 = 324 nM) and of comparable potency to the best
compound (20) in that series (EC50 = 174 nM). However, the
potencies of 33 and 34 in the β-arrestin assay were reduced by
1 order of magnitude as compared to parent compound 2.
Compound 36 containing the “bulkier” benzophenone
functionality at the C4 position showed no activity in the
cAMP assay and only residual activity in the β-arrestin assay, an
activity proﬁle justifying our decision not to pursue the
benzophenone analogue of 1.
To extend the functional proﬁling of what emerged from the
data presented above as our novel lead CB1R allosteric ligand,
20, we evaluated its activity in the guanosine 5′-O-(3-
[35S]thio)triphosphate ([35S]GTPγS) binding assay in mouse
brain membranes. This assay reﬂects the functional response of
GPCR ligands at the level of GDP/GTP exchange by the
ternary, agonist-activated GPCR−G protein complex, an event
that can modulate the activity of downstream eﬀector proteins.
The assay is considered reﬂective of the degree of G protein
activation following GPCR agonist engagement, an event more
Figure 2. Antagonism of CP55,940-dependent β-arrestin recruitment
(A) and cAMP inhibition (B) by CB1R analogues of 1 in vitro. (A)
CHO-K1 PathHunter hCB1R cells were pretreated with indicated test
compounds (0−10 μM) for 30 min followed by treatment with
CP55,940 (EC80) for 90 min. β-Arrestin recruitment was quantiﬁed
using the PathHunter assay. (B) CHO-K1 cAMP HitHunter hCB1
cells were pretreated with allosteric modulators (0−10 μM) for 30 min
followed by treatment with CP55,940 (EC80) for 30 min. cAMP
inhibition was quantiﬁed using the HitHunter assay. Data are
presented as % inhibition compared to maximal CP55,940 eﬀect ±
SEM from two independent replicates per assay. Derived data are
presented in Table 1.
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proximal to the GPCR itself in the biosignaling cascade than is
cAMP formation or G protein-independent β-arrestin signal-
ing.71 We observed that 20 inhibited CP55,940-induced
[35S]GTPγS binding to CB1R in mouse brain membranes by
progressively decreasing the Emax in a concentration-dependent
manner (Figure 4) with more eﬃcacy compared to 1. When
administered alone, 20 was “silent” and did not display CB1R
agonism or inverse agonism in the [35S]GTPγS binding assay
performed with mouse brain membranes (Figure 5). Also, 20
did not exhibit any signs of CB1R agonism or inverse agonism
in hCB1 CHO cell membranes up to 1 μM. A statistically
signiﬁcant, but much reduced, inverse agonism compared to 1
was observed only at suprapharmacological concentration (10
μM; data not shown). This compound has been extensively
studied for its CB1R NAM as well as inverse-agonist activity in
CB1R-mediated downstream signaling pathways and in diﬀer-
ent cell lines, where it consistently showed lack of inverse
agonism. The data are beyond the scope of this paper and will
be published elsewhere.
The activity proﬁle of 20 in the [35S]GTPγS binding assay is
in marked contrast to that reported for parent compounds 1
and 2, which elicit CB1R inverse-agonist activity in addition to
acting as CB1R NAM.26,41,42 To the best of our knowledge, this
is the ﬁrst report of a potent CB1R NAM lacking inverse
agonism. This functional distinction between 20 and the
standard CB1R NAMs 1 and 2 carries signiﬁcant translational
and rational drug-design implications. As detailed elsewhere,
CB1R inverse agonism has been associated with peripheral
(e.g., gastrointestinal) and central (e.g., psychobehavioral)
adverse events in preclinical animal models of disease and in
humans.21,23 The proposition has thus been advanced that
agents capable of attenuating CB1R information transmission
with intrinsically limited, if any, functional potency to elicit
negative-eﬃcacy responses might display an enhanced beneﬁt-
to-risk proﬁle as therapeutics relative to conventional CB1R
antagonists/inverse agonists for diseases with a pathogenic
component of CB1R hyperactivity.
Structural comparison between 1 and 20 implies that
modiﬁcations of 1 at C5 can generate CB1R NAMs that retain
the aﬃnity−eﬃcacy proﬁle of 1 but are devoid of or exhibit
reduced inverse-agonist activity of conventional CB1R NAMs.
To date, very limited SAR studies have been carried out with
variations at the C5 position. This work identiﬁes C5 position
as the key site for potential modiﬁcations for generating future
CB1 NAMs lacking inverse-agonist activity. This conclusion is
supported by recently published mutational and computational
data indicating that electrostatic interactions and van der Waals
forces between the nitrogen in the piperidine ring of 1 and the
Figure 3. Antagonism of CP55,940-dependent β-arrestin recruitment
(A) and cAMP inhibition (B) and by CB1R analogues of 2 in vitro.
Eﬀects on CP55,940-induced β-arrestin recruitment and cAMP
inhibition in the presence of various analogues of 2. (A) CHO-K1
PathHunter hCB1 cells were pretreated with allosteric modulators (0−
10 μM) for 30 min followed by treatment with CP55,940 for 90 min.
β-Arrestin recruitment was quantiﬁed using the PathHunter assay. (B)
CHO-K1 cAMP HitHunter hCB1 cells were pretreated with allosteric
modulators (0−10 μM) for 30 min followed by treatment with
CP55,940 for 30 min. cAMP inhibition was quantiﬁed using the
HitHunter assay. Data are presented as % inhibition compared to
maximal CP55,940 eﬀect ± SEM from two independent replicates per
assay. Derived data are presented in Table 2.
Table 1
cAMP accumulation β-arrestin recruitment
compound X Y EC50 (95% CI)
a Emax (%) ± SEM
b EC50 (95% CI)
a Emax (%) ± SEM
b
1 Cl H 324 (294−482) 78.1 ± 4.49 9.05 (6.63−12.4) 105 ± 2.10
19 N3 H 389 (332−459) 87.1 ± 3.02 28.2 (22.5−35.0) 105 ± 2.07
20 NCS H 174 (121−252) 111 ± 12.1 2.09 (1.24−3.53) 103 ± 1.38
25 Cl N3 1120 (962−1280) 96.8 ± 3.75 64.0 (51.0−80.2) 105 ± 2.70
26 Cl NCS >10000 −8.84 ± 1.18 209 (160−271) 107 ± 3.94
aNAM EC50 value (nM) in the presence of each designated test compound, determined using nonlinear regression analysis.
bMaximal NAM eﬀect,
determined using nonlinear regression analysis. Data are derived from Figure 2.
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CB1R aspartate residue D6.58(366) in CB1R transmembrane
helix 6 is crucial for inverse agonism such that the absence of
this nitrogen abrogates the inverse-agonism action of 1.42 In
our hands, even with the presence of the piperidine nitrogen,
20 did not evidence inverse agonism in mouse brain
membranes and hCB1 CHO cells (up to 1 μM). This result
invites the notion that the increased length of the NCS group at
C5 in 20 compared to the Cl group at that position in 1 might
extend 20 in its CB1R binding pocket slightly beyond 1’s
original docking position, potentially obviating or reducing the
interaction between the C5 nitrogen on the piperidine ring of
20 and that of the CB1R D6.58(366) residue, leading to loss of
inverse agonism.
■ LIGAND BINDING STUDIES
To proﬁle the ligand-binding characteristics of our lead CB1R
covalent ligand, 20, we ﬁrst evaluated the eﬀect of 20 on the
speciﬁc binding of the orthosteric ligand [3H]CP55,940 to
membranes obtained from CHO cells overexpressing hCB1R.
Both 20 and 1 signiﬁcantly enhanced the binding of
[3H]CP55,940 to hCB1 CHO cell membranes and acted as
CB1 PAM of binding. As indicated by the data shown in Figure
6, 20 produced this enhancement with signiﬁcantly greater
potency (lower EC50) than 1.
To investigate the ability of 20 to label the CB1R allosteric
site(s) covalently, we carried out time-course experiments
between 20 and hCB1R in membranes isolated from HEK293
cells overexpressing the receptor. We indexed the covalent
association between 20 and hCB1R as the extent to which a
preincubation of the isolated membranes with 20 at a
concentration of 500 nM followed by extensive membrane
washings with centrifugation inﬂuencing the subsequent level
(Bmax) of speciﬁc [
3H]CP55,940 binding to hCB1R in the
washed membranes. The binding of [3H]CP55,940 to hCB1R
increased in a time-dependent manner, reaching a maximum by
60 min preincubation time with isothiocyanate 20 (Figure 7).
Incubation of the CB1 receptor with 20 for 90 and 120 min
reduced speciﬁc binding of [3H]CP55,940. Presumably, the
extended incubation time (beyond 60 min) resulted in
nonspeciﬁc covalent modiﬁcation of the receptor and impaired
its ability to bind [3H]CP55,940. These data are consistent with
Table 2
aNAM EC50 value (nM) in the presence of each designated test compound, determined using nonlinear regression analysis.
bMaximal NAM eﬀect,
determined using nonlinear regression analysis. Data are derived from Figure 3.
Figure 4. [35S]GTPγS assay depicting the NAM eﬀect of increasing
concentrations of 20. Mean % increases in [35S]GTPγS binding to
mouse brain membranes induced by CP55,940 in the presence of
DMSO (n = 12) or 100 nM or 1 μM of 20 (n = 6) or 1 μM of 1 (n =
4). The mean Emax value of CP55,940 with its 95% conﬁdence interval
in parentheses is 94.3% (85.8−102.8%) in the presence of DMSO,
71.7% (65.3−78.1%) in the presence of 100 nM of 20, 11.2% (5.6−
16.8%) in the presence of 1 μM of 20, and 32.4% (24.0−40.8%) in the
presence of 1 μM of 1. Vertical lines show SEM values.
Figure 5. Activity of 20 and CP55,940 in the [35S]GTPγS assay. Mean
% changes in [35S]GTPγS binding to mouse brain membranes elicited
by CP55,940 or 20. The mean EC50 value of CP55,940 with a 95%
conﬁdence interval is 27.3 nM (7.2−103.2 nM, n = 6), and its
corresponding Emax value is 87.8% (67.9 and 107.7%). Vertical lines
show SEM values.
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the characteristic dependency of the association between
covalent ligands/probes and target proteins upon the length
of time the protein is incubated with the probe.60,62,47,57,58
The data in Figure 7 provided suﬃcient guidance to establish
experimental parameters for determining the eﬀect of 20 on
[3H]CP55,940 speciﬁc binding to hCB1R over a range of
radioligand concentrations in a saturation-binding assay. Parent
compound 1 was proﬁled in parallel as the nonderivatized
control lacking the chemically reactive isothiocyanate moiety
and, thus, incapable of covalently interacting with hCB1R. In
accord with our previous receptor-labeling studies,45−48 we
pretreated the HEK293 hCB1R membranes with either test
compound (500 nM, ﬁnal concn) for 60 min, subsequently
washed the membranes extensively to quench this incubation,
and quantiﬁed any change observed for the subsequent speciﬁc
binding of [3H]CP55,940 to hCB1R (as Bmax) in the washed
membranes. The saturation binding curves (Figure 8) show
that preincubation with 20 increased maximal hCB1R speciﬁc
binding of [3H]CP55,940 by ∼2.25-fold, whereas 1 had no
eﬀect. The combined data in Figures 7 and 8 indicate that 20
covalently labels hCB1R by virtue of its C5 isothiocyanate
group.
■ CONCLUSION
Adverse events associated with standard CB1R orthosteric
ligands (agonists and antagonists/inverse agonists) have
prompted alternative approaches in chemical pharmacology
for leveraging the translational potential of drug-like small-
molecules that modulate CB1R-dependent signaling. Predom-
inant in this newer thinking for enhancing therapeutics
targeting of CB1R are neutral antagonists with minimal, if
any, inverse-agonist eﬀects and allosteric ligands.23,24 Due to
greater receptor selectivity and ﬁner control over downstream
signaling than standard CB1R orthosteric modulators, CB1R
allosteric modulators oﬀer opportunities for novel pharmaco-
therapies with potentially enhanced safety and eﬃcacy proﬁles.
Rational design of CB1R allosteric modulators as drugs requires
greater understanding of the receptor’s allosteric binding site(s)
and the molecular pharmacology of ligands that are engaged by
Figure 6. Positive allosteric modulation of [3H]CP55,940 binding by
20 and 1. Eﬀects of 20, 1, and CP55,940 on [3H]CP55,940 binding to
hCB1 CHO cell membranes (n = 6). Mean values signiﬁcantly
diﬀerent from zero are indicated by the symbols * (for 20), # (for 1),
and • (for CP55,940); one symbol = P < 0.05; three symbols = P <
0.001; Student’s one sample t test). Positive values indicate
enhancement of [3H]CP55,940 binding. The mean Emax values of
20, 1, and CP55,940, with their 95% conﬁdence limits shown in
brackets, are 116.5% (108.3 and 124.6%), 109.3% (99.1 and 119.5%),
and −90.1% (−81.6 and −98.6%), respectively. The corresponding
EC50 values, again with 95% conﬁdence limits shown in brackets, are
19.6 nM (10.4 and 36.9 nM), 83.0 nM (44.1 and 156.2 nM), and 4.9
nM (2.6 and 9.0 nM).
Figure 7. Time-course studies showing the eﬀect of 20 preincubation
on CP55,940 binding. HEK293-hCB1R membranes incubated with
500 nM of 20 for 0 (control), 30, 60, 90, and 120 min.
Figure 8. Comparative covalent labeling of 20 (A) and 1 (B) with
hCB1R. Eﬀect of (A) 20 or (B) 1 on the saturation binding of [3H]
CP55,940 to HEK293-hCB1R cell membranes. Membranes were
incubated with allosteric ligands (500 nM) at 30 °C for 60 min and
extensively washed, followed by saturation binding of [3H]CP55,940
at concentrations ranging from 0 to 25 nM. Unbound [3H]CP55,940
was removed by washing−ﬁltration, and the membrane-bound
radioactivity was quantiﬁed. 1 did not label the receptor covalently
and hence did not aﬀect CP55,940 binding after wash, whereas 20
labeled the receptor covalently and caused ∼2.25 fold increase in
CP55,940 binding, as indexed by the respective Bmax values. Data
shown represent the mean ± SEM of three independent experiments
performed in duplicate.
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it. As part of our continued commitment to address this need,
we report our approach of derivatizing the classical CB1R
allosteric modulators 1 and 2 with a chemically reactive
electrophilic (NCS) or photoactivatable (azide and benzophe-
none) groups at the judiciously selected positions within each
molecule. Functional characterization demonstrated that these
novel analogues displayed the prototypical paradoxical
pharmacological properties which make them PAMs of
CP55,940 binding but NAM in function. With all of these
analogues and in the assay systems utilized, we observed a
consistent bias toward β-arrestin over cAMP-dependent
signaling. Among these, 20 emerged as the most potent
NAM in the cellular cAMP, G-protein-independent β-arrestin,
and G protein-dependent GTPγS functional assays, and it was
more potent than the parent compound 1. It was also more
potent than 1 as a PAM of orthosteric ligand binding. Notably,
when applied alone, 20 did not aﬀect the constitutive activity of
the receptor in the GTPγS assay, making it the ﬁrst ever
covalent, potent CB1R NAM without signiﬁcant inverse-
agonist activity, a property suggestive of a lower adverse-
event risk. Compound 20 engaged the CB1R allosteric site(s)
covalently, making this compound a unique and valuable probe
with which to help elucidate the (sub)molecular features of
ligand recognition and engagement by CB1R. Ongoing work in
this regard will incorporate 20 and newer-generation CB1R
allosteric covalent probes into our established LAPS paradigm
in conjunction with site-speciﬁc CB1R point mutations and
peptide-level LC/MS/MS for identifying experimental amino
acid residues critical to CB1R allosteric ligand binding/function
and mapping structural features and topology of the CB1R
allosteric ligand-binding pocket(s). Because preliminary data
indicate that binding of 20 to hCB1R is irreversible, the utility
of this compound as a structural probe may be extended to 20−
hCB1R cocrystallization studies aimed at mapping the location
of the CB1R allosteric site(s) and their atomic-level features.
■ METHODS
PathHunter CB1 β-Arrestin Assay. Chinese hamster ovary
K1 (CHO-K1)-PathHunter hCB1 β-arrestin cells (DiscoveRx,
Fremont, CA) were seeded at 5000 cells/well in 384-well plates
24 h before use and incubated at 37 °C, 5% CO2. Compounds
were dissolved in dimethyl sulfoxide (DMSO) and diluted in
optimized cell culture (OCC) media. Agonist EC80 was
determined directly from an agonist dose−response curve
(data not shown). The CP55,940 EC80 was 31.1 ± 0.47 nM
(mean ± SEM, n = 3 independent experiments). Five
microliters of allosteric modulator or vehicle solution was
added to each well at the appropriate concentrations and
incubated for 30 min. Five microliters of agonist was then
added to each well followed by a 90 min incubation. Fifteen
microliters of detection reagent was then added followed by
further 60 min incubation at room temperature. Chemilumi-
nescence was measured on a standard luminescence plate
reader as relative light units (RLU). Basal RLU was deﬁned as
zero. Results were calculated as the percentage inhibition of
CP55,940 maximal eﬀect. Data were analyzed using the four-
parameter variable-slope and allosteric EC50 shift nonlinear
regression equations in Prism 5.0 (GraphPad, San Diego, CA).
The results of this analysis are presented as Emax ± SEM, and
EC50 (nM) with 95% CI.
HitHunter cAMP Assay. Chinese Hamster Ovary K1
(CHO-K1)-HitHunter hCB1R cells (DiscoveRx) were seeded
at 10 000 cells/well in 384-well plates 24 h before use and
incubated at 37 °C under 5% CO2. Compounds were dissolved
in DMSO and diluted in OCC media. Agonist EC80 was
determined directly from an agonist dose−response curve (data
not shown). The CP55,940 EC80 was 7.5 ± 0.15 nM (mean ±
SEM, n = 3 independent experiments). Media was aspirated
and replaced with 10 μL of 1:1 HBSS/HEPES:cAMP XS+Ab
reagent containing 20 μM forskolin (DiscoveRx). Five
microliters of test compound or vehicle solution was added
to each well at the appropriate concentrations and incubated
for 30 min. Five microliters of agonist was then added to each
well followed by a 30 min incubation. Twenty microliters of
cAMP XS+ED/CL lysis cocktail (DiscoveRx) was then added
followed by 60 min incubation at room temperature. Finally, 20
μL of cAMP XS+EA reagent (DiscoveRx) was added followed
by 3 h incubation at room temperature. Chemiluminescence
was measured on a standard luminescence plate reader (as
RLUs). Basal RLU was deﬁned as zero. Results were calculated
as the percentage inhibition of CP55,940 maximal eﬀect. Data
were analyzed using the four-parameter variable slope and
allosteric EC50 shift nonlinear regression equations in Graph-
Pad Prism 5.0 (GraphPad, San Diego, CA). The results of this
analysis are presented as Emax ± SEM, and EC50 (nM) with 95%
CI.
Radioligand Displacement Assay. Chinese hamster
ovary (CHO) cells transfected with cDNA encoding human
cannabinoid CB1 receptors were maintained at 37 °C in
Dulbecco’s modiﬁed Eagle’s medium nutrient mixture F-12
HAM, supplemented with 1 mM L-glutamine, 10% fetal bovine
serum, 0.6% penicillin−streptomycin, and G418 (400 μg/mL).
All cells were exposed to 5% CO2 in their media, and were
passaged twice a week using nonenzymatic cell dissociation
solution. For membrane preparation, cells were removed from
ﬂasks by scraping, centrifuged, and then frozen as a pellet at
−20 °C until required. Before use in a radioligand binding
assay, cells were defrosted, diluted in Tris buﬀer (50 mM Tris-
HCl and 50 mM Tris-base), and homogenized with a 1 mL
hand-held homogenizer.
The assays were carried out with [3H]CP55,940 and Tris
binding buﬀer (50 mM Tris-HCl, 50 mM Tris-base, 0.1% BSA,
pH 7.4), total assay volume 500 μL, using the ﬁltration
procedure described previously.41,72 Binding was initiated by
the addition of transfected human CB1 CHO cell membranes
(50 μg of protein per well). All assays were performed at 37 °C
for 60 min before termination by the addition of ice-cold Tris
binding buﬀer, followed by vacuum ﬁltration using a 24-well
sampling manifold (Brandel Cell Harvester; Brandel Inc.,
Gaithersburg, MD) and Brandel GF/B ﬁlters that had been
soaked in wash buﬀer at 4 °C for at least 24 h. Each reaction
well was washed six times with a 1.2 mL aliquot of Tris binding
buﬀer. The ﬁlters were oven-dried for 60 min and then placed
in 3 mL of scintillation ﬂuid (Ultima Gold XR, PerkinElmer,
Seer Green, Buckinghamshire, UK). Radioactivity was
quantiﬁed by liquid scintillation spectrometry. Speciﬁc binding
was deﬁned as the diﬀerence between the binding that occurred
in the presence and absence of 1 μM unlabeled CP55,940. The
concentration of [3H]CP55,940 used in our displacement
assays was 0.7 nM. The compounds under investigation were
stored as 10 mM stock solutions in DMSO, the vehicle
concentration in all assay wells being 0.1% DMSO.
[35S]GTPγS Binding Assay. Mouse brain membranes (5 μg
protein), prepared as described previously,41 were preincubated
for 30 min at 30 °C with adenosine deaminase (0.5 IU/mL).
The membranes were then incubated with CP55,940 or 20, or
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with CP55,940 ± 20, 1, or vehicle, for 60 min at 30 °C in assay
buﬀer (50 mM Tris-HCl, 50 mM Tris-base, 5 mM MgCl2, 1
mM EDTA, 100 mM NaCl, 1 mM DTT, 0.1% BSA) in the
presence of 0.1 nM [35S]GTPγS and 30 μM GDP, in a ﬁnal
volume of 500 μL. Binding was initiated by the addition of
[35S]GTPγS. Nonspeciﬁc binding was measured in the
presence of 30 μM GTPγS. The reaction was terminated by
rapid vacuum ﬁltration (50 mM Tris-HCl, 50 mM Tris-base,
0.1% BSA) using a 24-well sampling manifold (cell harvester,
Brandel, Gaithersburg, MD) and GF/B ﬁlters (Whatman,
Maidstone, UK) that had been soaked in buﬀer (50 mM Tris-
HCl, 50 mM Tris-base, 0.1% BSA) for at least 24 h. Each
reaction tube was washed six times with a 1.2 mL aliquot of ice-
cold wash buﬀer. The ﬁlters were oven-dried for at least 60 min
and then placed in 3 mL of scintillation ﬂuid (Ultima Gold XR,
PerkinElmer, Seer Green, Buckinghamshire, UK). Radioactivity
was quantiﬁed by liquid scintillation spectrometry.
Data Analysis. Most results were calculated as percentage
changes from a basal level (zero) of [3H]CP55,940 or
[35S]GTPγS binding (in the presence of vehicle). GraphPad
Prism 5.0 (GraphPad, San Diego, CA) was used to construct
sigmoidal log concentration−response curves and to calculate
values of EC50, Emax, SEM, and 95% conﬁdence intervals. Some
mean values were compared using Student’s one sample t test.
P values <0.05 were considered to be signiﬁcant.
Rat Brain and HEK293 Cell Membrane Preparations.
Rat forebrain membranes for binding assays were prepared
according to a published protocol.73 HEK293 cells over-
expressing hCB1R were disrupted by cavitation in a pressure
cell, and membranes were sedimented by ultracentrifugation, as
described.46 The membrane pellet was resuspended in TME
buﬀer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, pH 7.4),
and membrane protein was quantiﬁed with a Bradford dye-
binding method (Bio-Rad Laboratories).
[3H] CP55,940 Saturation-Binding to hCB1 in the
Presence of Allosteric Ligands. Membrane preparations
either from rat brain or HEK293 cells overexpressing hCB1
receptor were resuspended in TME−BSA (TME containing
0.1% BSA), and aliquots of this suspension containing 25 μg of
proteins were added to each assay well. Membranes were
preincubated with 1 (for 1 h) or 20 (for 0, 30, 60, 90, and 120
min) at 500 nM concentration of allosteric ligand at 30 °C with
agitation. The excess ligand was removed during washes with
TME−BSA and TME buﬀers and centrifugations at 27 000g, 30
°C. Membrane proteins were quantiﬁed with a Bradford dye
binding method (Bio-Rad Laboratories). Saturation binding
assays were performed with the washed membranes and
[3H]CP55,940 radioligand at concentrations ranging between 0
and 25 nM. Nonspeciﬁc binding was evaluated in the presence
of 5 μM unlabeled CP55,940. The assay was performed at 30
°C for 1 h with gentle agitation. The resultant material was
transferred to Uniﬁlter GF/B ﬁlter plates and the unbound
ligand removed using a Packard Filtermate-96 Cell Harvester
(PerkinElmerPackard, Shelton, CT). Filter plates were washed
four times with ice-cold wash buﬀer (50 mM Tris base, 5 mM
MgCl2 containing 0.5% BSA, pH 7.4). Bound radioactivity was
quantiﬁed using the Packard top count scintillation counter.
Nonspeciﬁc binding was subtracted from the total bound
radioactivity to obtain the speciﬁc binding of [3H]CP-55,940
(represented as pmol/mg of protein). All assays were
performed in triplicate, and data points were represented as
the mean Bmax and Kd values, calculated by nonlinear regression
using Graphpad Prism 4.0 on a Windows platform.
The assay was performed in 200 μL of TME−BSA buﬀer at
30 °C for 1 h with gentle agitation. Filtration and washing were
performed as described above. Nonspeciﬁc binding was
subtracted from the total bound radioactivity to obtain
[3H]CP55,940 speciﬁc binding of (as pmol/mg protein). All
assays were performed in triplicate, and data points were
represented as the mean Bmax and Kd values, calculated by
nonlinear regression using GraphPad Prism 5.0.
■ EXPERIMENTAL SECTION
All commercial chemicals and solvents were purchased from Sigma-
Aldrich, Inc. (St. Louis, MO), Alfa Aesar, and Combi-blocks as reagent
grade and unless otherwise speciﬁed were used without further
puriﬁcation. Biotage Initiator microwave system was used for the
synthesis of a few of the intermediates of the ﬁnal covalent probes.
Reaction progress was monitored by thin-layer chromatography
(TLC) using commercially prepared silica gel 60 F254 glass plates.
Compounds were visualized under ultraviolet (UV) light or by staining
with iodine, phosphomolybdic acid, or p-anisaldehyde reagent. Flash
column chromatography was carried out on a Biotage SP1, Biotage
Isolera, or Interchim puriﬁcation unit using prepacked columns from
Reveleris, Biotage, and Luknova. Solvents used include hexanes, ethyl
acetate, acetone, methanol, and dichloromethane. Characterization of
compounds and their purity were established by a combination of
HPLC, TLC, mass spectrometry, and NMR analyses. NMR spectra
were recorded in DMSO-d6, chloroform-d, or methanol-d4, on a Varian
NMR spectrometer (1H NMR at 500 MHz and 13C NMR at 125
MHz). Chemical shifts were recorded in parts per million (δ) relative
to tetramethylsilane (TMS; 0.00 ppm) or solvent peaks as the internal
reference. Multiplicities are indicated as br (broadened), s (singlet), d
(doublet), t (triplet), q (quartet), quin (quintet), sept (septet), or m
(multiplet). Coupling constants (J) are reported in hertz (Hz). All test
compounds were greater than 95% pure as determined by LC/MS
analysis performed using a Agilent Technologies 1260 Inﬁnity reverse-
phase HPLC, with a dual-wavelength UV−visible detector and an
Agilent Technologies 6120 Quadrupole mass spectrometer (electro-
spray ionization).
5-Chloro-3-ethyl-N-[4-(piperidin-1-yl)phenethyl]-1H-indole-
2-carboxamide (1). To a mixture of 16a (500 mg, 2.24 mmol) and 8
(548 mg, 2.68 mmol) in 5 mL of anhydrous NMP under an argon
atmosphere and at room temperature were added HOBT (302 mg,
2.24 mmol), DIPEA (347 mg, 2.68 mmol), and EDCI (486 mg, 3.13
mmol), and the resulting mixture was stirred overnight. The reaction
mixture was diluted with cold water and the crude product was
extracted in ether (3×). The combined organic layer was washed with
water and brine and dried (Na2SO4). Volatiles were evaporated under
reduced pressure, and the crude product obtained was puriﬁed by ﬂash
column chromatography on silica gel (10−40%; EtOAc:hexanes) to
give 1 as a white solid (709 mg, 77% yield). Rf = 0.7 (EtOAc/hexanes
= 50/50). 1H NMR (500 MHz, chloroform-d): 9.28 (s, 1H), 7.54 (d, J
= 1.5 Hz, 1H), 7.29 (d, J = 9.0 Hz, 1H), 7.20 (dd, J = 8.5 Hz, J = 2.0
Hz, 1H), 7.14 (d, J = 8.5 Hz, 2H), 6.92 (d, J = 8.5 Hz, 2H), 6.04−5.94
(m, 1H,), 3.79 (q, J = 6.5 Hz, 2H), 3.13 (t, J = 5.5 Hz, 4H), 2.89 (t, J =
6.5 Hz, 2H), 2.69 (q, J = 8.0 Hz, 2H), 1.75−1.67 (m, 4H), 1.61−1.54
(m, 2H), 1.08 (t, J = 7.5 Hz, 3H). Mass spectrum m/z 410.18 [M +
H]+.
4-(Piperidin-1-yl)benzaldehyde (6). To a solution of 5 (20 g,
161.1 mmol) and piperidine (16.47 g, 193 mmol) in 60 mL of dry
NMP under an argon atmosphere was added anhydrous K2CO3 (44.5
g, 322 mmol), and the resulting solution was stirred at 135 °C for 12 h.
Reaction contents were allowed to cool to room temperature and were
diluted with ice cold water. Product was extracted in ether (3×), and
the combined organic layer was washed with water and brine and dried
over MgSO4. Solvent was evaporated under reduced pressure, and
puriﬁcation of the crude product by ﬂash column chromatography (0−
15%; EtOAc:hexanes) aﬀorded 6 as a pale yellow solid (23.78 g, 78.2%
yield). Rf = 0.5 (EtOAc/hexanes = 20/80).
1H NMR (500 MHz,
chloroform-d): δ 9.74 (s, 1H), 7.72 (d, J = 9.5 Hz, 2H), 6.89 (d, J = 9.0
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Hz, 2H), 3.45−3.37 (m, 4H), 1.74−1.63 (m, 6H). Mass spectrum m/z
190.12 [M + H]+.
(E)-1-[4-(2-Nitrovinyl)phenyl]piperidine (7). To a solution of 6
(20 g, 106 mmol) in 100 mL of anhydrous nitromethane was added
NH4OAc (24.44 g, 317 mmol) under an argon atmosphere, and the
resulting mixture was reﬂuxed for 2 h. Solvent was removed under
reduced pressure, and the reaction mixture was diluted with ethyl
acetate and water (2:1). The organic layer was separated, the aqueous
layer was extracted with ethyl acetate (3×), and the combined organic
layer was washed with water and brine and dried over MgSO4. The
solvent was evaporation under reduced pressure, and the crude
product was puriﬁed by ﬂash column chromatography (5%−20%;
EtOAc:hexanes) to give 7 as a dark orange solid (16.10 g, 65.6%
yield). Rf = 0.48 (EtOAc/hexanes = 20/80).
1H NMR (500 MHz,
chloroform-d): δ 7.95 (d, J = 13.5 Hz, 1H), 7.50 (d, J = 13.5 Hz, 1H),
7.42 (d, J = 9.0 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 3.40−3.36 (m, 4H),
1.74−1.63 (m, 6H). Mass spectrum m/z 233.12 [M + H]+.
2-(4-(Piperidin-1-yl)phenyl)ethanamine (8). To a cooled (5
°C) solution of 7 (15 g, 64.3 mmol) in 120 mL of anhydrous methanol
at 5 °C was added NaBH4 (14.66 g, 387 mmol) in small portions
under an argon atmosphere, and the reaction mixture was stirred for 2
h while allowing it to warm to room temperature. It was then
quenched with dropwise addition of 80 mL of saturated NH4Cl. The
mixture was concentrated under reduced pressure, and the crude
product was partitioned in ethyl acetate and water. The organic layer
was separated, the aqueous layer extracted with ethyl acetate (3×), and
the combined organic layer was washed with brine and dried over
Na2SO4. Evaporation of volatiles under reduced pressure gave a crude
mixture which was puriﬁed by ﬂash column chromatography (10%−
40%; EtOAc:hexanes) to yield the intermediate 1-(4-(2-nitroethyl)-
phenyl)piperidine as a pale yellow oil (12.8 g, 85% yield). Rf = 0.42
(EtOAc/hexanes = 20/80). 1H NMR (500 MHz, chloroform-d): δ
7.07 (d, J = 9.0 Hz, 2H), 6.88 (d, J = 9.0 Hz, 1H), 4.55 (t, J = 7.5 Hz,
2H), 3.23 (d, J = 7.5 Hz, 2H), 3.17−3.10 (m, 4H), 1.73−1.66 (m,
4H), 1.61−1.53 (m, 2H). Mass spectrum m/z 233.12 [M + H]+.
To a solution of this intermediate (12.5 g, 53.40 mmol) in 100 mL
of anhydrous THF and methanol (13:1) was added NiCl2·6H2O
(15.22 g, 64 mmol) under an argon atmosphere, and reaction mixture
was stirred for 45 min at room temperature. It was then cooled to −5
°C, and NaBH4 (12.11 g, 320 mmol) was added in small portions. The
reaction was then gradually warmed to room temperature, stirred for 3
h, quenched with saturated aqueous solution of NH4Cl, and
concentrated under reduced pressure. The residue was diluted with
ethyl acetate and water and ﬁltered. The organic layer was separated,
and the aqueous layer was extracted with ethyl acetate (3×). The
combined organic layer was washed with brine, dried (Na2SO4), and
evaporated under vacuum to yield pure amine 8 (8.8 g, 81% yield). Rf
= 0.81 (MeOH/DCM = 20/80). 1H NMR (500 MHz, chloroform-d):
δ 7.08 (d, J = 8.0 Hz, 2H), 6.89 (d, J = 8.0 Hz, 2H), 3.17−3.08 (m,
4H), 2.92 (t, J = 7.0 Hz, 2H), 2.66 (t, J = 7.0 Hz, 2H), 1.76−1.66 (m,
4H), 1.61−1.52 (m, 2H), 1.31 (br s, 2H). Mass spectrum m/z 205.16
[M + H]+.
4-Chlorobenzenediazonium Chloride (10a). To a suspension
of ﬁnely powdered 9a (2.54 g, 20 mmol) in 10 mL of 24% aq
hydrochloric acid at 0 °C was added a cold aqueous solution of sodium
nitrite (1.7 g, 23 mmol), and the reaction mixture was stirred for 1 h
while maintaining the temperature between 0 and 5 °C. The resulting
pale yellow solution of diazonium salt 10a was directly used for the
next reaction.
4-Nitrobenzenediazonium Chloride (10b). The compound was
synthesized as per the procedure described for 10a using nitroaniline
9b.The reaction solution of diazonium salt 10b was directly used for
the next reaction.
Ethyl-2-acetyl Pentanoate (12a). To a ﬂask containing 300 mL
of anhydrous ethanol at 10 °C was added sodium metal (6.0 g, 261.0
mmol) portionwise under an argon atmosphere, and the mixture was
stirred for 30 min to complete dissolution. To this was added ethyl
acetoacetate (34.0 g, 261.0 mmol), and the resulting solution was
reﬂuxed for 30 min and allowed to cool to room temperature. This was
followed by addition of iodopropane (11a, 44.44 g, 261.0 mmol) over
a period of 30 min through a dropping funnel, and the reaction
mixture was reﬂuxed for 12 h. The mixture was cooled to room
temperature and ﬁltered, and the ﬁltrate was neutralized by adding 1 N
hydrochloric acid, concentrated under reduced pressure, and
partitioned in ethyl acetate and water. The organic layer was separated,
the aqueous layer extracted with ethyl acetate (3×), and the combined
organic layer was washed with brined and dried over MgSO4. The
product was puriﬁed by ﬂash column chromatography (0%−20%;
EtOAc:hexanes) to give 12a as a clear liquid (35.1 g, 78% yield). Rf =
0.45 (EtOAc/hexanes = 20/80). 1H NMR (400 MHz, chloroform-d) δ
4.20 (q, J = 7.2 Hz, 2H), 3.42 (t, J = 7.2 Hz, 1H), 2.22 (s, 3H), 1.92−
1.76 (m, 2H), 1.40−1.20 (m, 5H, especially 1.28, t, J = 7.2 Hz, 3H),
0.93 (t, J = 7.2 Hz, 3H). Mass spectrum m/z 172.10 [M + H]+.
Ethyl 2-Acetyl-4-(1,3-dioxoisoindolin-2-yl)butanoate (12c).
To a 500 mL ﬂask containing 150 mL of anhydrous acetone were
added ethyl acetoacetate (10.0 g, 77.0 mmol) and K2CO3 (11.68 g, 85
mmol), and the mixture was stirred for 2 h at room temperature. To
this was added 2-(3-iodopropyl)isoindoline-1,3-dione (11c; 24.21 g,
77.0 mmol) and reﬂuxed overnight. The mixture was ﬁltered through a
Buchner funnel, and the ﬁltrate was cooled to room temperature.
Volatiles were evaporated, water was added to the crude product, and
the resultant mass was acidiﬁed to pH 4. The aqueous layer was
extracted in dichloromethane (2×), and the combined organic layer
was dried over MgSO4 and triturated in hexane to obtain the desired
compound 12c as a white solid (18.31 g, 75.1% yield). 1H NMR (500
MHz, DMSO-d6) δ 7.87−7.82 (m, 2H), 7.74−7.69 (m, 2H), 4.19 (qd,
J = 7.0 Hz, 2.0 Hz, 2H), 3.71 (t, J = 7.0 Hz, 2H), 3.50 (t, J = 7.0 Hz,
1H), 2.25 (s, 3H), 1.96−1.81 (m, 2H), 1.78−1.63 (m, 2H), 1.26 (t, J =
7.0 Hz, 3H). Mass spectrum m/z 332.15 [M + H]+.
General Procedure for Synthesis of Substituted Indole-2-
carboxylates. To a solution of 2-alkylated ethyl acetoacetate 12 (2.9
mmol) in 30 mL of ethanol was added NaOAc (6.12 mmol) under an
argon atmosphere, and the resulting mixture was stirred at room
temperature for 45 min, followed by cooling to 0 °C. Aryldiazonium
salt 10 was added to the reaction along with additional NaOAc to
maintain the pH at 5, and the resulting solution was stirred for 3 h
while maintaining the temperature between 0 and 5 °C. The reaction
was quenched by adding saturated aqueous NaHCO3 solution, and the
volatiles were removed under reduced pressure. The mixture was
extracted with ethyl acetate (3×), the organic layer was washed with
water and brine and dried over Na2SO4. The solvent was removed
under vacuum to give the crude product as red oil which was a mixture
of corresponding azo and hydrazone (13 and 14) intermediates. This
mixture was passed through a small column of silica and dried under
high vacuum to give a thick orange-brown mass. To this mass was
added 100 mL of 20% sulfuric acid in anhydrous ethanol and was
reﬂuxed for 24 h. The reaction mixture was cooled to room
temperature and neutralized by adding aqueous NaHCO3 solution.
Crude product was extracted with ethyl acetate (3×). The combined
organic layer was washed with water and brine, dried over Na2SO4, and
concentrated under vacuum to yield a crude mixture which was
puriﬁed by ﬂash column chromatography on silica gel (0%−20%;
EtOAc: hexanes) to give pure desired indole esters 15.
Ethyl 5-Chloro-3-ethyl-1H-indole-2-carboxylate (15a). The
compound was synthesized as per the general procedure as a white
solid (64% yield). Rf = 0.35 (EtOAc/hexanes = 20/80).
1H NMR (400
MHz, chloroform-d): δ 8.74 (br s, 1H), 7.65 (d, J = 1.2 Hz, 1H), 7.30
(d, J = 8.8 Hz, 2H), 7.25 (dd, J = 8.8 Hz, J = 1.2 Hz, 1H), 4.42 (q, J =
7.2 Hz, 2H), 3.07 (q, J = 7.2 Hz, 2H), 1.43 (t, J = 7.2 Hz, 3H), 1.26 (t,
J = 7.2 Hz, 3H). Mass spectrum m/z 251.07 [M + H]+.
Ethyl 3-Ethyl-5-nitro-1H-indole-2-carboxylate (15b). The
compound was synthesized as per the general procedure as a pale
white solid (57% yield). Rf = 0.35 (EtOAc/hexanes = 20/80).
1H
NMR (400 MHz, chloroform-d): δ 9.02 (s, 1H), 8.69 (d, J = 2.0 Hz,
1H), 8.22 (dd, J = 8.8 Hz, J = 2.4 Hz, 1H), 7.43 (d, J = 9.6 Hz, 1H),
4.46 (q, J = 7.6 Hz, 2H), 3.16 (q, J = 7.2 Hz, 2H), 1.45 (t, J = 7.6 Hz,
3H), 1.31 (t, J = 7.2 Hz, 3H). Mass spectrum m/z 263.11 [M + H]+.
Ethyl 5-Chloro-3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-1H-in-
dole-2-carboxylate (15c). The compound was synthesized as per
the general procedure as a white solid (71% yield). 1H NMR (500
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MHz, DMSO-d6): δ 11.73 (s, 1H), 7.79 (s, 4H), 7.63 (d, J = 1.5 Hz,
1H), 7.38 (d, J = 8.5 Hz, 1H), 7.20 (dd, J = 8.0 Hz, 1.5 Hz, 1H), 4.19
(q, J = 7.0 Hz, 2H), 3.83 (t, J = 6.0 Hz, 2H), 3.35 (t, J = 6.0 Hz, 2H),
1.27 (t, J = 6.5 Hz, 3H). Mass spectrum m/z 397.09 [M + H]+
5-Chloro-3-ethyl-1H-indole-2-carboxylic Acid (16a). To a
solution of 15a (330 mg, 1.31 mmol) in 30 mL of dioxane was
added a solution of KOH (440 mg, 7.7 mol) in 3 mL of water, and the
resulting solution was reﬂuxed for 2 h. It was then cooled to room
temperature, concentrated under reduced pressure, and neutralized by
addition of 1 N hydrochloric acid. The precipitated acid was ﬁltered,
washed with cold water, and air-dried to give pure acid 16a (306 mg,
98% yield) as white solid. 1H NMR (500 MHz, DMSO-d6): δ 13.04 (s,
1H), 11.57 (s, 1H,), 7.71 (s, 1H), 7.40 (d, J = 9.0 Hz, 1H), 7.23 (dd, J
= 9.0 Hz, 2.0 Hz, 1H), 3.03 (q, J = 7.5 Hz, 2H), 1.16 (t, J = 7.5 Hz,
3H). Mass spectrum m/z 224.04 [M + H]+.
3-Ethyl-5-nitro-1H-indole-2-carboxylic Acid (16b). The com-
pound was synthesized as per the procedure for 16a, as a solid (72%
yield). 1H NMR (400 MHz, DMSO-d6): δ 12.14 (s, 1H), 8.67 (d, J =
2.0 Hz, 1H), 8.11 (dd, J = 8.8 Hz, 2.5 Hz, 1H), 7.54 (d, J = 8.8 Hz,
1H), 3.12 (q, J = 8.0 Hz, 2H), 1.22 (t, J = 7.6 Hz, 3H). Mass spectrum
m/z 235.06 [M + H]+.
3-Ethyl-5-nitro-N-[4-(piperidin-1-yl) phenethyl]-1H-indole-2-
carboxamide (17). The compound was synthesized as per the
procedure for 1, as a solid (82% yield). Rf = 0.7 (EtOAc/hexanes =
50/50). 1H NMR (500 MHz, chloroform-d): δ 9.97 (s, 1H), 8.58 (d, J
= 2.0 Hz, 1H), 8.16 (dd, J = 9.5 Hz, J = 2.0 Hz, 1H), 7.44 (d, J = 9.5
Hz, 1H), 7.15 (d, J = 8.5 Hz, 2H), 6.93 (d, J = 8.5 Hz, 2H), 6.18−6.07
(m, 1H), 3.82 (q, J = 6.0 Hz, 2H), 3.14 (t, J = 5.5 Hz, 4H), 2.91 (t, J =
7.0 Hz, 2H), 2.79 (q, J = 7.5 Hz, 2H), 1.76−1.68 (m, 4H), 1.62−1.54
(m, 2H), 1.13 (t, J = 7.5 Hz, 3H). Mass spectrum m/z 421.22 [M +
H]+.
5-Amino-3-ethyl-N-[4-(piperidin-1-yl)phenethyl]-1H-indole-
2-carboxamide (18). To a solution of 17 (600 mg, 1.43 mmol) in 30
mL of anhydrous THF and anhydrous methanol (13:1) was added
NiCl2·6H2O (356 mg, 1.49 mmol) under an argon atmosphere, and
reaction mixture was stirred at room temperature for 45 min. The
mixture was then cooled to −5 °C to which was added NaBH4 (324
mg, 8.56 mmol) portionwise, and the reaction was gradually warmed
to room temperature while stirring for 1 h. Reaction was quenched
with saturated NH4Cl and concentrated under reduced pressure. The
residue was diluted with ethyl acetate and water and ﬁltered, the
organic layer was separated, and the aqueous layer was extracted with
ethyl acetate (3×). The combined organic layer was washed with water
and brine, dried (Na2SO4), and evaporated under vacuum to yield 18
(479 mg, 86% yield). Rf = 0.8 (MeOH/DCM = 20/80).
1H NMR
(500 MHz, DMSO-d6): δ 10.60 (s, 1H), 7.74 (t, J = 5.5 Hz, 1H), 7.08
(d, J = 9.0 Hz, 3H), 6.85 (d, J = 9.0 Hz, 2H), 6.69 (d, J = 2.0 Hz, 1H),
6.62 (dd, J = 9.0 Hz, 2.0 Hz, 1H), 4.56 (br s, 2H), 3.44 (q, J = 6.5 Hz,
2H), 3.06 (t, J = 5.5 Hz, 4H), 2.90 (q, J = 7.5 Hz, 2H), 2.74 (t, J = 7.5
Hz, 2H), 1.64−1.56 (m, 4H), 1.54−1.46 (m, 2H), 1.11 (t, J = 7.5 Hz,
3H). Mass spectrum m/z 390.24 [M + H]+.
5-Azido-3-ethyl-N-[4-(piperidin-1-yl)phenethyl]-1H-indole-
2-carboxamide (19). To a solution of 18 (400 mg, 1.10 mmol) in 40
mL of THF under argon atmosphere was added tert-butyl nitrite (1.6
g, 15.5 mmol) and TMSN3 (1.2 g, 10.42 mmol), and the reaction was
stirred overnight at room temperature. Solvent was evaporated under
reduced pressure to give crude product which was puriﬁed using ﬂash
column chromatography on silica gel (10%−40%; EtOAc:hexanes) to
yield pure 19 as a brown solid (180 mg, 42.0% yield). Rf = 0.81
(MeOH/DCM = 20/80). 1H NMR (500 MHz, chloroform-d): δ 9.14
(s, 1H), 7.35 (d, J = 9.0 Hz, 1H), 7.20 (d, J = 2.0 Hz, 1H), 7.14 (d, J =
9.0 Hz, 2H), 6.95 (dd, J = 9.0 Hz, J = 2.0 Hz, 1H), 6.92 (d, J = 9.0 Hz,
2H), 5.98 (br t, J = 6.0 Hz, 1H,), 3.78 (q, J = 6.5 Hz, 2H), 3.13 (t, J =
5.5 Hz, 4H), 2.89 (t, J = 6.5 Hz, 2H), 2.70 (q, J = 8.0 Hz, 2H), 1.75−
1.68 (m, 4H), 1.64−1.54 (m, 2H), 1.08 (t, J = 8.0 Hz, 3H). Mass
spectrum m/z 417.23 [M + H]+.
3-Ethyl-5-isothiocyanato-N-[4-(piperidin-1-yl)phenethyl]-
1H-indole-2-carboxamide (20). To a solution of 18 (400 mg, 1.10
mmol) in 5 mL of CH2Cl2 was added di(2-pyridyl) thionocarbonate
(308 mg, 1.32 mmol), and the reaction mixture was stirred at room
temperature for 15 min. It was quenched with cold water and extracted
with dichloromethane (3×), and the combined organic layer was
washed with brine, dried on Na2SO4, and evaporated under vacuum.
The resultant residue was puriﬁed on silica gel (5%−25%;
EtOAc:hexanes) to give pure compound 20 (388 mg, 87% yield). Rf
= 0.35 (EtOAc/hexanes = 20/80). 1H NMR (400 MHz, chloroform-
d): δ 9.79 (s, 1H), 7.46 (s, 1H), 7.35 (d, J = 8.8 Hz, 1H), 7.17−7.09
(m, 3H, especially 7.14, d, J = 8.0 Hz, 2H), 6.92 (d, J = 8.0 Hz, 2H),
6.03 (br t, J = 6.4 Hz, 1H), 3.80 (q, J = 6.0 Hz, 2H), 3.13 (br t, J = 5.6
Hz, 4H), 2.90 (t, J = 6.4 Hz, 2H), 2.70 (q, J = 7.6 Hz, 2H), 1.76−1.67
(m, 4H), 1.62−1.54 (m, 2H), 1.08 (t, J = 7.6 Hz, 3H). Mass spectrum
m/z 433.21 [M + H]+.
3-(2-Aminoethyl)-5-chloro-1H-indole-2-carboxylic Acid (21).
To a solution of 15c (10.0 g, 25.2 mmol) in 200 mL of ethanol was
added ethanolamine (3.08 g, 50.4 mmol), and the reaction mixture was
reﬂuxed for 14 h. It was then cooled to room temperature, volatiles
were removed under vacuum, and the mixture was partitioned in ethyl
acetate and water. The organic layer was separated, the aqueous layer
was extracted with ethyl acetate (3×), and the combined organic layer
was washed with brine and dried over Na2SO4. The solvent was
removed under vacuum to give the lactam intermediate as a pure white
solid (4.9 mg, 88% yield). Rf = 0.2 (EtOAc/hexanes = 50/50).
1H
NMR (500 MHz, DMSO-d 6) δ 11.81 (s, 1H), 7.68 (d, J = 2.0 Hz,
1H), 7.66 (s, 1H), 7.39 (d, J = 9.0 Hz, 1H), 7.21 (dd, J = 7.0 Hz, 1.5
Hz, 1H), 3.54 (t, J = 4.0 Hz, 2H), 2.92 (t, J = 4.0 Hz, 2H). Mass
spectrum m/z 221.04 [M + H]+.
To this intermediate (4.5 g, 20.39 mmol) in 100 mL of
dioxane:H2O (4:1) was added KOH (6.87 g, 122.0 mmol) in excess,
and the mixture was reﬂuxed overnight. It was then cooled to room
temperature, and the volatiles were removed under vacuum. The
residue was diluted with ice cold water and acidiﬁed to pH 5 with
concd hydrochloric acid to give a precipitate which was ﬁltered and air-
dried to give the desired 21 as a white solid. (4.77 g, 98% yield). Rf =
0.15 (MeOH/DCM = 20/80). 1H NMR (500 MHz, DMSO-d6) δ
11.19 (s, 1H), 8.79 (br s, 3H), 7.62 (d, J = 2.0 Hz, 1H), 7.33 (d, J = 8.5
Hz, 1H), 7.08 (dd, J = 8.5 Hz, J = 2.0 Hz, 1H), 3.18 (t, J = 6.0 Hz,
2H), 3.01 (t, J = 6.0 Hz, 2H). Mass spectrum m/z 239.05 (M + H)+.
3-(2-((tert-Butoxycarbonyl)amino)ethyl)-5-chloro-1H-indole-
2-carboxylic Acid (22). To a solution of 21 (4.0 g, 16.76 mmol) in
80 mL of THF was added Boc anhydride (3.84 g, 17.60 mmol) at 0
°C. To this were added 50 mL of aq saturated NaHCO3 solution and
water (2:1), and the reaction mixture was stirred at 0 °C for 3 h and
then allowed to warm up to room temperature and stirred for 24 h.
Solvent was then removed under vacuum, ice cold water was added to
the residue, and it was acidiﬁed to pH 5 with cold 5% aq hydrochloric
acid. The resultant precipitate was ﬁltered, and the residue was washed
with cold water and air-dried to give crude product as a cream colored
solid which was recrystallized in methanol to give pure desired product
22 (5.0 g, 88% yield). Rf = 0.25 (MeOH/DCM = 10/90).
1H NMR
(500 MHz, DMSO-d6) δ 11.59 (s, 1H), 7.68 (s, 1H), 7.39 (d, J = 8.5
Hz, 1H), 7.20 (dd, J = 8.5 Hz, J = 1.5 Hz, 1H), 6.87 (t as br s, 1H),
3.16 (t, J = 8.5 Hz, 2H), 3.15 (t, J = 8.5 Hz, 2H), 1.31 (s, 9H). Mass
spectrum m/z 339.11 [M + H]+.
tert-Butyl (2-(5-Chloro-2-((4-(piperidin-1-yl)phenethyl)-
carbamoyl)-1H-indol-3-yl)ethyl)carbamate (23). The compound
was synthesized by coupling 22 with 8 as per the procedure for 1, as a
white solid (68% yield). Rf = 0.8 (EtOAc/hexanes = 50/50).
1H NMR
(500 MHz, chloroform-d) δ 9.39 (s, 1H), 7.64 (s, 1H), 7.54 (d, J = 2.0
Hz, 1H), 7.32 (d, J = 8.5 Hz, 1H), 7.21 (dd, J = 8.5 Hz, 2.0 Hz, 1H),
7.15 (d, J = 8.0 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 4.92 (br s, 1H), 3.75
(dd, J = 15.5 Hz, 6.5 Hz, 2H), 3.21 (dd, J = 16.0 Hz, 6.0 Hz, 2H), 3.11
(t, J = 6.0 Hz, 4H), 3.09−3.03 (m, 2H), 2.95 (t, J = 8.0 Hz, 2H), 1.70
(quint, J = 5.5 Hz, 4H), 1.58−1.54 (m, 2H), 1.49 (s, 9H). Mass
spectrum m/z 526.25 [M + H]+.
3-(2-Aminoethyl)-5-chloro-N-(4-(piperidin-1-yl)phenethyl)-
1H-indole-2-carboxamide (24). To 100 mL of CH2Cl2 was added
23 (2.0 g, 3.81 mmol) followed by dropwise addition of 10 mL of
TFA, and the reaction was stirred at room temperature for 3 h.
Volatiles were then removed under vacuum, and the crude product
was washed with saturated NaHCO3 and extracted in dichloromethane
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(3×). The combined organic layer was washed with brine, dried over
Na2SO4, and evaporated under vacuum to give 24 as a white solid
(1.47 g, 91% yield). Rf = 0.2 (MeOH/DCM = 20/80).
1H NMR (500
MHz, chloroform-d) δ 10.32 (t as br s, 1H), 9.85 (s, 1H), 7.47 (d, J =
2.0 Hz, 1H), 7.34 (d, J = 8.5 Hz, 1H), 7.18 (dd, J = 9.0 Hz, 2.0 Hz,
1H), 7.13 (d, J = 9.0 Hz, 2H), 6.89 (d, J = 8.5 Hz, 2H), 3.72 (q, J = 6.5
Hz, 2H), 3.12 (t, J = 5.5 Hz, 4H), 2.94−2.84 (m, 6H), 1.76−1.66 (m,
4H), 1.62−1.52 (m, 2H), 1.35 (s, 2H). Mass spectrum m/z 426.20 [M
+ H]+.
3-(2-Azidoethyl)-5-chloro-N-(4-(piperidin-1-yl)phenethyl)-
1H-indole-2-carboxamide (25). To a 10 mL solution of NaN3 (2.07
g, 31.9 mmol) in H2O was added triﬂuoromethanesulfonyl anhydride
(3.0 g, 10.63 mmol) in DCM at 0 °C and stirred for 2 h while
maintaining the temperature. The organic layer was separated, the
aqueous layer was extracted with DCM (2×), and the organic layers
were combined to aﬀord TfN3. In a separate round-bottom ﬂask, a
solution of 24 (1.0 g, 2.35 mmol) in 20 mL of H2O:methanol (1:20)
was treated with K2CO3 (2.6 g, 18.83 mmol) and CuSO4 (751 mg,
4.71 mmol). To this mixture was added the above TfN3 solution, and
it was stirred at room temperature for 18 h. Volatiles were then
removed under vacuum, and the residue was dissolved in DCM,
washed with water and brine, and dried over Na2SO4. The organic
layer was concentrated under vacuum, and the crude product was
puriﬁed on silica gel (0%−20%; EtOAc:hexanes) to obtain 25 as a
pure compound (679 mg, 64%). Rf = 0.7 (EtOAc/hexanes = 50/50).
1H NMR (500 MHz, chloroform-d) δ 11.49 (s, 1H), 8.16−8.06 (m,
1H), 7.75 (s, 1H), 7.43 (d, J = 8.5 Hz, 1H), 7.21 (d, J = 8.5 Hz, 1H),
7.09 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.0 Hz, 2H), 3.56−3.42 (m, 4H),
3.24 (t, J = 7.0 Hz, 2H), 3.13−3.01 (m, 4H), 2.76 (t, J = 7.0 Hz, 2H),
1.67−1.55 (m, 4H), 1.55−1.44 (m, 2H). Mass spectrum m/z 452.19
[M + H]+.
5-Chloro-3-(2-isothiocyanatoethyl)-N-(4-(piperidin-1-yl)-
phenethyl)-1H-indole-2-carboxamide (26). To a solution of 24
(1.0 g, 2.353 mmol) in 50 mL of CH2Cl2 was added di(2-pyridyl)
thionocarbonate (656 mg, 2.82 mmol), and the reaction mixture was
stirred at room temperature for 15 min. It was quenched with cold
water and extracted with dichloromethane (3×), and the combined
organic layer was washed with brine, dried on Na2SO4, and evaporated
under vacuum. The resultant residue was puriﬁed on silica gel (5%−
25%; EtOAc:hexanes) to give pure compound 26 (956 mg, 87%
yield). Rf = 0.35 (EtOAc/hexanes = 20/80).
1H NMR (500 MHz,
DMSO-d6) δ 11.52 (s, 1H), 8.17 (t, J = 5.5 Hz, 1H), 7.81 (d, J = 2.0
Hz, 1H), 7.44 (d, J = 8.5 Hz, 1H), 7.22 (ddd, J = 8.5 Hz, 2.0 Hz, 1.0
Hz, 1H), 7.10 (d, J = 8.5 Hz, 2H), 6.86 (d, J = 8.5 Hz, 2H), 3.82 (t, J =
7.0 Hz, 2H), 3.48 (q, J = 7.0 Hz, 2H), 3.38 (t, J = 7.0 Hz, 2H), 3.07 (t,
J = 5.5 Hz, 4H), 2.76 (t, J = 7.0 Hz, 2H), 1.65−1.56 (m, 4H), 1.56−
1.46 (m, 2H). Mass spectrum m/z 468.16 [M + H]+.
2-Bromo-6-(pyrrolidin-1-yl)pyridine (29). A mixture of 27
(10.0 g, 42.2 mmol) and 28 (13.87 mL, 169 mmol) was stirred for
1 h at room temperature. The reaction mixture was quenched with 100
mL of saturated NaHCO3 solution and diluted with 100 mL of
dichloromethane. The organic layer was separated, washed with water
and brine, and dried (MgSO4) and concentrated under reduced
pressure. The resulting crude product was crystallized from methanol
(50 mL) to aﬀord the desired product 29 (8.5 g, 37.4 mmol, 89%
yield) as a white solid. 1H NMR (500 MHz, methanol-d4) δ: 7.22 (t, J
= 8.0 Hz, 1H), 6.64 (d, J = 7.5 Hz, 1H), 6.23 (d, J = 8.0 Hz, 1H), 3.43
(t, J = 6.5 Hz, 4H), 2.04−1.94 (m, 4H). Mass spectrum m/z 228.01
[M + H]+.
2-(3-Nitrophenyl)-6-(pyrrolidin-1-yl)pyridine (30). To a sol-
ution of 29 (2 g, 8.81 mmol) and 3-nitrophenylboronic acid (1.62 g,
9.69 mmol) in 1,2-dimethoxyethane (10 mL) were added Ba(OH)2
(3.32 g, 19.37 mmol) and water (4 mL) under argon atmosphere. The
contents were degassed, Pd(Ph3P)4 (0.305 g, 0.26 mmol) was added,
and the resulting mixture was irradiated with microwaves at 150 °C for
15 min. It was then diluted with 200 mL of ethyl acetate and water
(1:1), and the organic layer was separated, washed with water and
brine, and dried over MgSO4. Volatiles were concentrated under
reduced pressure to give crude product which was puriﬁed by silica gel
chromatography (20−70%; EtOAc:hexanes) to give 30 (2.05 g, 86%
yield) as a yellow solid. 1H NMR (500 MHz, DMSO-d6) δ: 8.57 (t, J =
1.5 Hz, 1H), 8.50 (td, J = 8.0 Hz, J = 1.5 Hz, 1H), 8.23 (ddd, J = 8.0
Hz, J = 2.5 Hz, J = 1.0 Hz, 1H), 7.74 (t, J = 8.0 Hz, 1H), 7.63 (dd, J =
8.0 Hz, J = 7.0 Hz, 1H), 7.28 (d, J = 7.0 Hz, 1H), 6.51 (d, J = 8.0 Hz,
1H), 3.49 (t, J = 6.5 Hz, 4H), 2.04−1.94 (quin, J = 3.0 Hz, 4H). Mass
spectrum m/z 270.1 [M + H]+.
3-(6-(Pyrrolidin-1-yl)pyridin-2-yl)aniline (31). To a solution of
30 (5 g, 18.57 mmol) in methanol (100 mL) was added catalytic
amounts of Raney-nickel, and the resultant mixture was stirred for 3 h
under hydrogen atmosphere. Raney-nickel was ﬁltered oﬀ and, ﬁltrate
was concentrated and puriﬁed by silica gel chromatography (20−70%;
EtOAc:hexanes) to give 31 (4.25 g, 96% yield) as a whitish solid. 1H
NMR (500 MHz, chloroform-d) δ: 7.52−7.48 (m, 1H), 7.46 (t, J = 2.0
Hz, 1H), 7.45−7.41 (m, 1H), 7.29 (s, 1H), 7.23 (t, J = 8.0 Hz, 1H),
6.99 (d, J = 7.0 Hz, 1H), 6.72 (ddd, J = 5.5 Hz, J = 2.5 Hz, J = 1.0 Hz,
1H), 3.75 (br s, 2H), 3.57 (t, J = 6.5 Hz, 4H), 2.08−1.80 (m, 4H).
Mass spectrum m/z 240.2 [M + H]+.
1-(4-Azidophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)-
phenyl)urea (33). To a solution of triphosgene (70 mg, 0.21 mmol)
in toluene (10 mL) was added 31 (130 mg, 0.54 mmol) followed by
Et3N (2.4 mL, 23.6 mmol) under inert atmosphere, and the mixture
was heated to 70 °C for 3 h under argon atmosphere. The reaction was
concentrated under reduced pressure and carried forward to the next
step without any puriﬁcation. To a solution of this isocyanate
intermediate in DCM (4 mL) was added 4-azidoaniline 32 (72 mg,
0.167 mmol) followed by Et3N (2.4 mL, 23.6 mmol), and the mixture
was stirred at 0 °C for 6 h. The reaction mixture was diluted in 20 mL
of DCM and water (1:1). The organic layer was separated, washed
with water, dried (Na2SO4), and concentrated under reduced pressure.
The crude product was puriﬁed by silica gel chromatography (10−
50%; EtOAc:hexanes) to aﬀord the desired product 33 (150 mg, 75%
yield) as white solid. 1H NMR (500 MHz, DMSO-d6) δ 8.78 (s, 1H),
8.75 (s, 1H), 8.07 (t, J = 2.0 Hz, 1H), 7.63 (dt, J = 7.5 Hz, 1.5 Hz,
1H), 7.56 (dd, J = 8.5 Hz, 7.0 Hz, 2H), 7.52 (d, J = 9.0 Hz, 2H) 7.34
(t, J = 7.5 Hz, 1H), 7.08−7.03 (m, 3H), 6.42 (d, J = 9.0 Hz, 1H),
3.54−3.42 (m, 4H), 2.04−1.92 (m, 4H). Mass spectrum m/z 400.18
[M + H]+.
1-(4-Isothiocyanatophenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-
2-yl)phenyl)urea (34). To a solution of 33 (25 mg, 0.06 mmol) in 5
mL of benzene under an argon atmosphere was added triphenylphos-
phine (34.2 mg, 0.12 mmol), and the reaction mixture was reﬂuxed for
4 h. The reaction mixture was cooled to room temperature, 1 mL of
CS2 was added to this, and the reaction mix was stirred at 40 °C for 12
h. Volatiles were evaporated under reduced pressure to obtain crude
product which was puriﬁed using ﬂash column chromatography
(10%−40%; EtOAc:hexanes) to obtain pure 34 as a white solid (17
mg, 74% yield). Rf = 0.78 (MeOH/DCM = 20/80).
1H NMR (500
MHz, DMSO-d6) δ 8.96 (s, 1H), 8.84 (s, 1H), 8.07 (t, J = 2.0 Hz, 1H),
7.64 (d, J = 7.5 Hz, 1H), 7.59−7.51 (m, 4H, esp. 7.54, d, J = 9.5 Hz,
2H), 7.38 (d, J = 9.0 Hz, 2H), 7.35 (t, J = 7.0 Hz, 1H), 7.06 (d, J = 7.5
Hz, 1H), 6.42 (d, J = 8.5 Hz, 1H), 3.54−3.42 (m, 4H), 2.04−1.92 (m,
4H). Mass spectrum m/z 416.15 [M + H]+.
1-(4-Benzoylphenyl)-3-(3-(6-(pyrrolidin-1-yl)pyridin-2-yl)-
phenyl)urea (36). To a solution of triphosgene (23 mg, 0.77 mmol)
in toluene (2 mL) was added 35 (40 mg, 0.16 mmol) followed by
Et3N (0.78 mL, 7.8 mmol) under inert atmosphere, and the mixture
was heated to 70 °C for 3 h under argon atmosphere. The reaction was
concentrated under reduced pressure and carried forward to the next
step without any puriﬁcation.
To this intermediate dissolved in THF (10 mL) was added 31 (39
mg, 0.167 mmol) followed by Et3N (0.78 mL, 7.8 mmol), and the
mixture was stirred at 0 °C for 1 h and then at room temperature for 5
h. The reaction mixture was concentrated under reduced pressure, and
crude product was recrystallized from methanol to give desired
product 36 (60 mg, 78% yield) as a white solid. 1H NMR (500 MHz,
DMSO-d6) δ 9.19 (s, 1H), 8.92 (s, 1H), 8.10 (t, J = 2.0 Hz, 1H), 7.75
(d, J = 9.0 Hz, 2H), 7.71 (dd, J = 8.0 Hz, 1.5 Hz, 2H), 7.69−7.63 (m,
4H), 7.61−7.53 (m, 4H), 7.37 (t, J = 8.0 Hz, 1H), 7.07 (d, J = 7.5 Hz,
1H), 6.43 (d, J = 8.5 Hz, 1H), 3.54−3.45 (m, 4H), 2.03−1.93 (m,
4H). Mass spectrum m/z 463.21 [M + H]+.
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